Bridging the gap in the fight against tuberculosis.
Identifying the most effective new drugs for tuberculosis will depend on developing systems for preclinical testing that better reflect conditions in the diseased host and the characteristics of persistent M tuberculosis. Integrating information from these diverse new technologies using a model-based approach to antituberculosis drug development could facilitate more effective use of this information in transitioning novel compounds successfully to the clinical phase.